

## Claims

1. (Original) ZnT-1 for use as a cellular L-type calcium channel (LTCC) blocker, which blocker has the properties of:
  - (a) a modulator of LTCC function; and
  - (b) a modulator of intracellular calcium concentration.
2. (Currently Amended) ZnT-1 of claim 1, for use as an LTCC blocker in the treatment [and/] or prevention of cardiovascular diseases and related indications.
3. (Currently Amended) ZnT-1 of claim 1 [any one of claims 1 and 2], for use in the treatment [and/] or prevention of hypertension and stroke.
4. (Currently Amended) ZnT-1 of claim 1 [any one of claims 1 to 3], wherein said ZnT-1 is active in any one of vascular, brain or heart cells.
5. (Original) A composition for blocking L-type calcium channels, comprising as active agent ZnT-1, and optionally comprising pharmaceutically acceptable adjuvant, carrier, diluent or excipient.
6. (Currently Amended) The composition of claim 5, for the treatment [and/] or prevention of cardiovascular diseases and related indications.
7. (Currently Amended) The composition of claim 6, for the treatment [and/] or prevention of hypertension and stroke.
8. (Currently Amended) A method of treating cardiovascular disorders in a patient in need of such treatment, comprising administering to said patient ZnT-1 or the composition [of any one of claims 5 to 7] comprising as active

agent ZnT-1, and optionally comprising pharmaceutically acceptable adjuvant, carrier, diluent or excipient.

9. (Currently Amended) Use of ZnT-1 in the preparation of a pharmaceutical composition for the treatment [and/] or prevention of cardiovascular diseases and related indications, preferably said cardiovascular diseases are hypertension and stroke.
10. (New) The method of claim 8, wherein said disorder comprises hypertention or stroke.